VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.3323
-0.0173 (-4.95%)
At close: Sep 8, 2026, 4:00 PM EDT
0.3317
-0.0179 (-5.12%)
Pre-market: Sep 9, 2026, 7:26 AM EDT
VolitionRx Revenue
VolitionRx had revenue of $398.66K in the quarter ending June 30, 2026, a decrease of -1.97%. This brings the company's revenue in the last twelve months to $2.46M, up 86.32% year-over-year. In the year 2025, VolitionRx had annual revenue of $1.73M with 40.04% growth.
Revenue (ttm)
$2.46M
Revenue Growth
+86.32%
P/S Ratio
1.92
Revenue / Employee
$43,124
Employees
57
Market Cap
4.72M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.73M | 493.87K | 40.04% |
| Dec 31, 2024 | 1.23M | 458.21K | 59.10% |
| Dec 31, 2023 | 775.30K | 468.91K | 153.04% |
| Dec 31, 2022 | 306.39K | 216.36K | 240.30% |
| Dec 31, 2021 | 90.04K | 76.60K | 570.25% |
| Dec 31, 2020 | 13.43K | -3.66K | -21.43% |
| Dec 31, 2019 | 17.10K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 54.97K | - | - |
| Dec 31, 2011 | - | - | - |
| Aug 31, 2011 | - | - | - |
| Aug 31, 2010 | - | - | - |
| Aug 31, 2009 | - | - | - |
| Aug 31, 2008 | - | - | - |
| Aug 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vivos Therapeutics | 20.90M |
| WORK Medical Technology Group LTD | 10.72M |
| Beyond Air | 7.69M |
| Intelligent Bio Solutions | 4.22M |
| IceCure Medical | 3.95M |
| ENvue Medical | 1.93M |
| Co-Diagnostics | 721.39K |
| Nexalin Technology | 217.16K |
VNRX News
- 1 day ago - VolitionRx Registration statement: Registration filing - Filings
- 11 days ago - VolitionRx files to sell 10.01M shares of common stock for holders - TheFly
- 12 days ago - VolitionRx Registration statement: Registration filing - Filings
- 13 days ago - VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets - PRNewsWire
- 13 days ago - VolitionRx announces publication on Nu.Q NETs H3.1 biomarker - TheFly
- 13 days ago - Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis - PRNewsWire
- 23 days ago - VolitionRx reports results from lateral flow finger prick sample test for sepsis - TheFly
- 23 days ago - VolitionRx reports Q2 revenue $400K, consensus $474.34K - TheFly